SP
DGX icon

Stablepoint Partners’s Quest Diagnostics DGX Stock Holding History

Stablepoint Partners’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.11M Buy
14,652
+26
+0.2% +$5.1K 0.43% 80
2026
Q1 		$2.87M Sell
14,626
-139
-0.9% -$27K 0.43% 76
2025
Q4 		$2.56M Buy
14,765
+15
+0.1% +$2.73K 0.4% 81
2025
Q3 		$2.81M Sell
14,750
-24
-0.2% -$4.26K 0.45% 70
2025
Q2 		$2.65M Sell
14,774
-203
-1% -$35.3K 0.45% 72
2025
Q1 		$2.53M Sell
14,977
-543
-3% -$89.2K 0.46% 70
2024
Q4 		$2.34M Buy
15,520
+268
+2% +$41.7K 0.43% 75
2024
Q3 		$2.37M Buy
15,252
+120
+0.8% +$17.9K 0.43% 73
2024
Q2 		$2.15M Buy
15,132
+1,067
+8% +$146K 0.42% 76
2024
Q1 		$1.87M Buy
14,065
+2,299
+20% +$298K 0.38% 82
2023
Q4 		$1.62M Buy
+11,766
New +$1.55M 0.42% 70

Other funds holding DGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

Stablepoint Partners's DGX Position: Q2 2026 in Review

Stablepoint Partners increased its Quest Diagnostics (DGX) stake by 0.18% in Q2 2026, buying an estimated $5.1K and bringing the position to 14,652 shares worth $3.11M. The position accounts for 0.43% of the portfolio, ranked #80.

Stablepoint Partners first reported a position in DGX in Q4 2023 and has held it in 11 quarters since. 1,099 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

  • Stablepoint Partners held 14,652 shares of Quest Diagnostics worth $3.11M as of Q2 2026.
  • Stablepoint Partners bought 26 Quest Diagnostics shares in Q2 2026, an estimated $5.1K.
  • Quest Diagnostics made up 0.43% of Stablepoint Partners's portfolio in Q2 2026, its #80 holding.
  • Stablepoint Partners first reported a position in Quest Diagnostics in Q4 2023 and has held it in 11 quarters since.
  • 1,099 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on Stablepoint Partners's 13F filing for Q2 2026, filed 9 Jul 2026.